Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 22, 2014 17:23 ET | Source: Merrimack Pharmaceuticals

Merrimack Pharmaceuticals to Present Clinical Data Across Oncology Pipeline at ASCO 2014

CAMBRIDGE, Mass., May 22, 2014 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced it will present clinical data on four novel antibody cancer therapeutics at the 2014...
May 07, 2014 16:01 ET | Source: Merrimack Pharmaceuticals

Merrimack Pharmaceuticals to Present at the Bank of America Merrill Lynch 2014 Health Care Conference

CAMBRIDGE, Mass., May 7, 2014 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced that Ulrik Nielsen, Chief Scientific Officer, is scheduled to present at the Bank of...
May 01, 2014 06:01 ET | Source: Merrimack Pharmaceuticals

Merrimack Pharmaceuticals Reports First Quarter 2014 Financial Results

CAMBRIDGE, Mass., May 1, 2014 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK), a biopharmaceutical company discovering, developing and preparing to commercialize innovative medicines...
May 01, 2014 06:00 ET | Source: Merrimack Pharmaceuticals

Merrimack Pharmaceuticals Announces MM-398 Achieves Primary Endpoint of Overall Survival in Phase 3 Trial in Post-Gemcitabine Metastatic Pancreatic Cancer

MM-398 in combination with 5-fluorouracil and leucovorin demonstrates statistically significant advantage compared to control arm Plan to submit New Drug Application in 2014 Conference Call...
April 08, 2014 08:00 ET | Source: Merrimack Pharmaceuticals

Merrimack Announces Preliminary Data From Pilot Diagnostic Imaging Study of MM-398

CAMBRIDGE, Mass., April 8, 2014 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced Phase 1 results from a clinical pilot study demonstrating that ferumoxytol*, an iron...
March 31, 2014 08:00 ET | Source: Merrimack Pharmaceuticals

Merrimack to Present at the 2014 American Association for Cancer Research Annual Meeting

CAMBRIDGE, Mass., March 31, 2014 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced that it will present at the 2014 AACR Annual Meeting. The conference will take place...
February 27, 2014 16:01 ET | Source: Merrimack Pharmaceuticals

Merrimack Provides Fourth Quarter and Full Year 2013 Financial Results

CAMBRIDGE, Mass., Feb. 27, 2014 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK), a biopharmaceutical company discovering, developing and preparing to commercialize innovative...
February 24, 2014 08:00 ET | Source: Merrimack Pharmaceuticals

Merrimack to Present at the Cowen and Company 34th Annual Health Care Conference

CAMBRIDGE, Mass., Feb. 24, 2014 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced that Ulrik Nielsen, Chief Scientific Officer, is scheduled to present at the Cowen and...
February 20, 2014 16:05 ET | Source: Merrimack Pharmaceuticals

Merrimack Announces Timing of Fourth Quarter 2013 Investor Conference Call

CAMBRIDGE, Mass., Feb. 20, 2014 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced that the company will host its Fourth Quarter 2013 Investor Conference Call and...
February 18, 2014 08:00 ET | Source: Merrimack Pharmaceuticals

Preclinical Study Results of Merrimack's MM-141 Published in Molecular Cancer Therapeutics

CAMBRIDGE, Mass., Feb. 18, 2014 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced that the manuscript "MM-141, an IGF-1R- and ErbB3-Directed Bispecific Antibody,...